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2Abstract
The potential role for vitamin D and its active metabolite 1, 25-hydroxyvitamin D
(1,25(OH)2D) in modulating the immune response was first recognized 25 years ago. The
presence of adequate levels of vitamin D is required for the proper functioning of the body’s
defense system such as barrier integrity, the production of antimicrobials, chemotaxis of other
immune cells and regulation of inflammation in the innate and adaptive immune system.
We identified 60 studies on vitamin D and immune response. A total
of 33 studies were excluded because it was not clinical trials, of the  remaining 27, 21 were
excluded because clinical trials were not randomized controlled trials and one was
excluded because of using combined vitamin D and calcium, so the remaining five
clinical trials were reviewed to evaluate the clinical evidence for the role of vitamin D in the
immune system.
From the five Randomized Controlled Trials (RCTs) were reviewed in this paper, it is
concluded that the results from these studies appear quite robust and consistent. Side effect
profile of vitamin D  preparations were minimal and rare as indicated by reports of post
marketing surveilence as well as RCTs.
3Abstrak
Potensi peran vitamin D dan metabolit aktifnya 1,25-hidroksivitamin D (1,25(OH)2D)
dalam respons imun  telah dikenal sejak 25 tahun yang lalu. Vitamin D dalam kadar yang
cukup dibutuhkan agar sistem pertahanan tubuh dapat berfungsi dengan baik seperti integritas
sawar, produksi antimikroba, kemotaksis dari sel imun dan regulasi inflamasi dalam sistem
imun nonspesifik maupun spesifik.
Penelusuran awal berhasil mengidentifikasi 60 penelitian mengenai vitamin D dan
respons imun. Sebanyak 33 penelitian dieksklusi karena bukan merupakan uji klinis, dari 27
yang tersisa, 21 penelitian dieksklusi karena bukan uji klinik acak terkontrol dan satu
dieksklusi karena menggabungkan vitamin D dan kalsium, sehingga tersisa lima uji klinik
yang ditelaah untuk mengevaluasi bukti klinis peran vitamin D dalam respons imun.
Dari lima RCT yang diikutkan pada telaah sistematik ini, dapat disimpulkan bahwa
hasil penelitian-penelitian tersebut cukup kuat dan konsisten. Profil efek samping sediaan
vitamin D minimal dan jarang terjadi seperti diindikasikan baik dalam laporan post marketing
surveilence maupun RCT.
Background
The nonclassic tissues that have vitamin D receptors are those not only participating
in the classic actions of vitamin D such as bone, gut, and kidney. They are potential targets
for the active metabolite of vitamin D, 1,25(OH)2D1.
The presence of adequate levels of Vitamin D is required for the proper functioning of
the body’s defense system such as barrier integrity, the production of antimicrobials,
chemotaxis of other immune cells and regulation of inflammation in the innate and adaptive
immune system. In each disorder, the level of 25(OH)D that is needed for maximal
4performance has not been determined but may be considerably higher than previously
believed for diseases such as M. tuberculosis and other infections2.
In this review, we sought to evaluate the clinical evidence for the role of vitamin D in
the immune system by examining the effectiveness of vitamin D supplementation when used
as a stand-alone supplementation in the treatment of diseases and to examine the quality of
the published data.
Objective
To determine the beneficial effects of daily vitamin D in improving low level chronic
inflammation and immune response.
Methods
Inclusion criteria:
Research that will be included in this systematic review is all double-blind randomized
clinical trial with parallel or cross-over design on the effect of vitamin D on inflammation
and immune response.
The types of intervention to be studied are all forms of intervention with vitamin D in any
preparations, compared with placebo, given through all routes of drug administrations.
Evidence Acquisition:
We searched for articles in: MEDLINE (2000-2011), the Cochrane Database of
Systematic Reviews (Cochrane Collaboration, 2000-2011), CISCOM (Centralised
Information Service for Complementary Medicine), EMBASE (Excerpta Medica, 2000-
2011),
5The general structure of search strategy  carried out are (vitamin D OR synonyms)
AND (immune OR synonyms) AND (inflammation OR synonyms). Searches are
limited in English but not apply the filter methodology. We used the following keywords and
medical subject headings:
immunity, immune response, immune system, immunology
1,25(OH)2D, vitamin D, cholecalciferol
inflammation
To complete the primary search, we also performed  a search by combining (vitamin D or
synonims) and (immunity or synonims).
These resources were supplemented by the handsearching of articles’ bibliographies,
nonindexed medical and professional journals, and the Indonesian-language and English-
language libraries and files of the authors.
Data collection and analysis
All titles and abstracts obtained from electronic searches   databases and other searches was
conducted by three persons (LI, NA, and PT). Potential full articles meeting inclusion
criteria then were downloaded. Three reviewers (LI, NA, and PT) conducted an
assessment of study eligibility according to inclusion criteria and data extraction.
Quality Scoring
The quality of controlled clinical trials was examined based on the method of Jadad, a
method for assessing the quality of controlled clinical trials
Basic Jadad Score is assessed based on the answer to the following 5 questions.
The maximum score is 5.
6Question Yes No
1. Was the study described as random? 1  0
2. Was the randomization scheme described and appropriate? 1  0
3. Was the study described as double-blind? 1  0
4. Was the method of double blinding appropriate? (Were both the patient and the
assessor appropriately blinded?)
1  0
5. Was there a description of dropouts and withdrawals? 1  0
Quality Assessment Based on Jadad Score
Range of Score Quality
0–2 Low
3–5 High
7Result
In our initial screening, we identified 60 studies on vitamin D and immune response. A total
of 33 studies were excluded because it was not clinical trials, of the  remaining 27, 21 were
excluded because clinical trials were not randomized controlled trials and one was
excluded because of using combined vitamin D and calcium, so
the remaining five clinical trials were evaluated. Summary of the search process can be
seen in Figure 1 while the characteristics of the included studies in this systematic review are
summarized inTable 1.
Figure 1. Summary of the search process
initial screening:
60 studies
33  not
clinical trials
21 not RCTs
1 combined vitamin D
with calcium
5 RCTs are included in this
review
27 clinical trials
8Table 1. Human studies with vitamin D supplementation relating to the Immune Function
Referensi Dose Subjects
n
Duration
of
treatment
Outcome  result discussion Jada
d
Score
Adverse
efeect
Schleithof
f, et al.,
20063.
50 _g
vitamin
D3/d plus
500 mg
Ca/d [D(+)
group] or
placebo
plus
500mgCa/d
[D(–)
group]
Ninety-
three
patients
with CHF
9 mo survival
rate and
different
biochemica
l variables
Significant
treatment effects were
observed on logarithmic-
transformed serum
concentrations of 25-
hydroxyvitamin D,
parathyroid
hormone, tumor necrosis
factorα, and  IL 10
Vitamin D3 reduces
the inflammatory
milieu in CHF
patients and might
serve as a new
antiinflammatory
agent for the
future treatment of
the disease
2
(low)
NA
9Wejse et
al., 20094.
Use of 100
000 IU
365 adult
patients
with TB
starting
antituber
culosis
treatment
; 281
complete
d
at 1, 5 and
8 months.
clinical
outcome
and
mortality.
Vitamin D does not improve
clinical outcome among
patients withTB and no
overall effect on mortality
Dose may not be high
enough to
result in a difference
5
(high)
No
serious
adverse
effects
were
reported;
mild
hypercalc
emia was
rare and
present in
both
arms.
Nursyam,
E. W. et al
5.
10 000 IU
vitamin D
sixty
seven
tuberculo
six weeks clinical
improveme
nt,
77.1% sputum conversion
rate in
Highly
significant
2 (low) NA
10
daily sis
patient
nutritional
status,
sputum
conversion,
and
radiologica
l
improveme
nt
antibiotic only group
(placebo)
compared with 100% in
vitamin D
group
results.
However,
small sample
size
Bishoff-
Ferrari,
H. et al 6.
800 or 2000
IU
daily
cholecalcife
rol
173
patients
with
acute hip
fracture
12 months Primary
outcome
was rate
of falls;
secondary
outcome
was rate of
39% reduction in hospital
readmission in
the group using 2000 IU
daily
cholecalciferol, but  did not
reduce
falls
90% reduction
in infection
rate
5 (high) NA
11
hospital
readmissio
ns
Urashima,
M.
et al 7.
1200 IU
vitamin D
334
schoolchi
ldren
4 months
incidence
of seasonal
influenza A
RR of 0.58 compared with
control group p=0.04
Asthma attacks significantly
reduced in treatment group
p=0.006
(secondary outcome)
Significant
reduction of
influenza A but
not B
5 (high) NA
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Discussion
The potential role for vitamin D and its active metabolite 1,25(OH)2D in modulating
the immune response was first recognized 25 yr ago with three crucial discoveries: 1) the
presence of vitamin D receptors (VDRs) in activated human inflammatory cells, 2) the ability
of 1,25(OH)2D to inhibit T cell proliferation, and 3) the ability of disease activated
macrophages to produce 1,25(OH)2D (i.e. express CYP27B1). Vitamin D and CYP27B1
play important roles in both innate and adaptive immunity, which impact a number of clinical
conditions 1.
For example, a low vitamin D status is involved in various infectious diseases such as
tuberculosis, and 1,25(OH)2D3 has long been considered to potentiate the killing of
mycobacteria by monocytes. The underlying mechanism of these observations has recently
been found by the observation that the monocyte, when activated by mycobacterial
lipopeptides, expresses CYP27B1, producing 1,25(OH)2D from circulating 25OHD and in
turn inducing cathelicidin, an antimicrobial peptide that increases killing of the
mycobacterium. Inadequate 25OHD levels fail to support this process. As a second example,
it has been discovered that vitamin D deficiency and/or living at higher latitudes (with less
sunlight) are linked with a number of autoimmune diseases including type 1 diabetes
mellitus, multiple sclerosis, and Crohn’s disease. In a large Finnish study, giving infants 2000
IU vitamin D for their first year of life decreased the incidence of type 1 diabetes mellitus by
80%. Other studies have related vitamin D deficiency to high risk of multiple sclerosis,
asthma, and other immunologic diseases1.
Epidemiological data showed that Upper Respiratory Infection (URI) incidence has
been inversely associated with 25(OH)D3 levels. In a randomized, double-blind trial of
vitamin D supplementation, vitamin D was shown to have no effect on the clinical course of
URIs 8.
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In 2006 Cannell et al9. proposed that children who received vitamin D supplements
had a low incidence of respiratory infections and linked this observation to vitamin D
regulation of the antimicrobial peptides cathelicidin and defensin b2. Vitamin D has been
shown to enhance the expression of antibacterial peptides; however, the effect of vitamin D
on these antibacterial peptides in vitro or in vivo against influenza has not been tested10.
From  a  public  health  point  of  view,  the  improved  outcomes  in  treatment  of  and
prevention of devastating diseases as summarized in Table 1 may result in considerable cost
savings to health care.
Conclusions and Limitation
The nonclassic actions of vitaminD are cell specific and provide a number of potential
new clinical applications for 1,25(OH)2D3 and its analogs. However, the use of vitamin D
metabolites  and  analogs  for  these  applications  remains  limited  by  the  classic  actions  of
vitamin D leading to hypercalcemia and hypercalcuria.
In this systematic review we conducted a search of the double-blind randomized
clinical trial on the effect of vitamin D in improving low-level chronic inflammation
and immune response. It was found that five clinical trials met  inclusion criteria, they
were clinical trials on the effects of vitamin D on postoperative complications,
incidence of influenza A, and different biochemical and clinical variables of tuberculosis and
CHF. Almost all of the studies were conducted with good methodology.
The effectiveness of vitamin D is shown with a reduction of the incidence of
influenza A,  the inflammatory milieu in CHF Patients, hospital readmission, and  increasing
sputum conversion rate.  Only one study showed that vitamin D did not improve
clinical outcome among patients with TB and overall effect on mortality but it  may be
caused by the  dose was not high enough.
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It is concluded that the results from these studies appear quite robust and consistent.
Furthermore, there is an increasing amount of data from experimental data suggesting
mechanisms for observed beneficial effects.
Side effect profile of vitamin D preparations are good enough as indicated by report
of side effects that were minimal and rare. Much still needs to be learned in this area of study.
It appears appropriate to call for new and innovative studies using appropriate doses of
vitamin D, which may greatly reduce morbidity and mortality worldwide.
Limitation
In the five clinical trials, outcomes measured were not the same and measurement
techniques  were also varied. Search on this systematic review was also conducted only in
English.  This has the potential to cause   bias because study reported in other languages can
not be found.
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Nursyam et al.11 was  to  assess  the  benefit  of  vitamin  D were clinical improvement,
nutritional status, sputum conversion, and radiological improvement. Primary  outcome  of
Bischoff-Ferrari et al. study was rate of falls, secondary outcome was rate of hospital
readmissions during the 12-month follow-up. The primary outcome of Wejse et al.7 study
was to assess the benefit of vitamin D on clinical improvement as assessed by TBscore. The
Objectives of Martineau et al. study was to determine the effect of vitamin D
supplementation on antimycobacterial immunity and vitamin D status while  Kawaura et al12.
study aimed to know the effect of long term supplementation with 1α hydroxyvitamin D3 on
serum pepsinogen and gastrin levels and rate of H. pylori infection.
